Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





MeMed Highlights Pioneering Blood Test for Accurately Distinguishing Between Bacterial and Viral Infection

By LabMedica International staff writers
Posted on 26 Apr 2022

MeMed (Haifa, Israel) hosted an integrated symposium, oral presentation and poster spotlighting MeMed BV at the 32nd European Congress of Clinical Microbiology and Infectious Diseases Conference (ECCMID) in Lisbon, Portugal, April 23-26, 2022. More...

Clinical key opinion leaders presented clinical use and performance data in scientific sessions, including an integrated symposium, oral abstract presentation and poster abstract on MeMed BV performance validation data.

MeMed BV is a pioneering blood test to help physicians with the seemingly simple clinical dilemma - does a patient have a bacterial or viral infection. The test harnesses the power of the body’s immune system and delivers results in just 15 minutes. MeMed BV measures and computationally integrates the levels of three immune system proteins: TRAIL, IP-10 and CRP. MeMed BV is the only test for distinguishing bacterial from viral infections that has been validated in multinational, double-blind and external clinical studies. The clinical studies demonstrating the diagnostic performance of MeMed BV encompassed thousands of patients and are published in high impact medical journals.

Unlike most conventional solutions that seek to detect bacteria or viruses, MeMed BV is an advanced host response test that uses the human immune system as the disease sensor. This approach offers unique advantages far beyond speed and accuracy: (i) It can diagnose cases when the infection site is not readily accessible or is unknown (e.g., pneumonia or fever without source) because immune markers circulate throughout the body; (ii) It can prevent false alarms due to detection of bacteria or viruses that are mere bystanders and are not causing the disease; (iii) It is robust to rapidly evolving pathogens. The MeMed BV test runs on MeMed Key, a cutting edge, compact immunoassay platform that is accurate and easy to use, making it possible to conduct highly sensitive, rapid, multiplexed protein measurements that previously could only be done on expensive central lab equipment.

Related Links:
MeMed 


Gold Member
Automatic Hematology Analyzer
DH-800 Series
Portable Electronic Pipette
Mini 96
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: When assessing the same lung biopsy sample, research shows that only 18% of pathologists will agree on a TCMR diagnosis (Photo courtesy of Thermo Fisher)

Molecular Microscope Diagnostic System Assesses Lung Transplant Rejection

Lung transplant recipients face a significant risk of rejection and often require routine biopsies to monitor graft health, yet assessing the same biopsy sample can be highly inconsistent among pathologists.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.